TradeFlare's AI research teams analysed ABUS on 15 market nights between April 22, 2026 and September 29, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 29, 2026 | HOLD | $4.86 | — / — | -4.5% | not yet | The current setup does not warrant a BUY recommendation, necessitating a HOLD to reassess future opportunities. |
| September 28, 2026 | HOLD | $4.85 | — / — | -3.9% | not yet | The current setup does not warrant a trade due to conflicting signals and high risk. |
| September 25, 2026 | HOLD | $4.88 | — / — | -8.2% | not yet | The current setup does not warrant a BUY, and the market regime is neutral, suggesting caution. |
| September 24, 2026 | HOLD | $4.85 | — / — | -6.6% | not yet | The current setup does not warrant a trade, and the stock's risk profile necessitates a cautious approach. |
| September 22, 2026 | HOLD | $5.00 | $5.75 / $4.25 | -6.4% | not yet | The stock is consolidating near resistance with mixed signals, and a clear directional bias is not yet established. |
| September 21, 2026 | HOLD | $5.01 | — / — | -2.8% | not yet | The current setup does not warrant a BUY recommendation, thus no defined time horizon for a trade. |
| August 31, 2026 | HOLD | $5.07 | $5.90 / $4.31 | +2.0% | -7.7% | The stock is trading near resistance and the risk/reward is not compelling enough for a buy. |
| July 16, 2026 | BUY | $4.56 | — / — | -5.7% | -3.4% | Inclusion in Russell Defensive Indexes. |
| May 14, 2026 | HOLD | $4.31 | — / — | +2.1% | -2.1% | Continued positive sentiment from the Moderna settlement and FDA Fast Track designation. |
| April 30, 2026 | BUY | $4.13 | — / — | +3.6% | +8.6% | Arbutus Biopharma's workforce reduction may signal a strategic shift towards cost efficiency and improved margins. |
| April 29, 2026 | HOLD | $4.15 | — / — | +7.0% | +11.4% | FDA Fast Track designation for imdusiran. |
| April 28, 2026 | BUY | $4.28 | — / — | +6.0% | +11.8% | Arbutus Biopharma Corp filed an 8-K on 2026-04-15 announcing a workforce reduction. |
| April 27, 2026 | BUY | $4.20 | — / — | +2.6% | +8.4% | Arbutus Biopharma Corp filed an 8-K on 2026-04-15 announcing a workforce reduction. |
| April 23, 2026 | BUY | $4.43 | — / — | -1.2% | +4.5% | Arbutus Biopharma's workforce reduction may signal a strategic shift towards cost discipline and improved margins. |
| April 22, 2026 | BUY | $4.43 | — / — | -6.8% | -1.4% | The current market conditions and the stock's fundamental and risk profiles do not support a buy decision. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.